Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cellobiose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.54 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.46 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AMY2A | P04746 | 3/20 | 0.53 |
| ▸ | TYR | P14679 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.49 |
| ▸ | GJA1 | P17302 | 1/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltotriose SCHEMBL2377340 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL16786 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373436 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL2229473 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Water SCHEMBL466158 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL19582547 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373437 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL7072560 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL1308532 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltose SCHEMBL230121 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447149-B2 | Formulations of vimseltinib | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-10-21 | — | — | US | claimed |
| US-20250205161-A1 | FORMULATIONS OF VIMSELTINIB | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | claimed |
| US-20250205236-A1 | FORMULATIONS OF VIMSELTINIB | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | claimed |
| US-20250195487-A1 | FORMULATIONS OF A CSF-1R INHIBITOR | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-19 | — | — | US | claimed |
| WO-2025129021-A1 | FORMULATIONS OF A CSF-1R INHIBITOR | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025122952-A1 | FORMULATIONS OF VIMSELTINIB | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-12 | — | — | WO | claimed |
| EP-3731829-B1 | TABLET COMPOSITIONS OF FESOTERODINE FUMARATE | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2024-07-17 | — | — | EP | claimed |
| EP-4188338-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, d.d., Novo mesto (SI) | 2023-06-07 | — | — | EP | claimed |
| CN-115677416-A | Production and processing method of selenium-rich nutrient fertilizer | 深圳新军科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2022023206-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, D.D., NOVO MESTO (SI) | 2022-02-03 | — | — | WO | claimed |
| CN-111418656-A | Composite soybean milk and preparation process thereof | 淮北徽香昱原早餐工程有限责任公司 | 2020-07-17 | — | — | CN | claimed |
| JP-4827296-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| EP-1083885-B1 | DELAVIRDINE TABLET FORMULATION | PHARMACIA & UPJOHN CO LLC (US) | 2006-12-27 | — | — | EP | claimed |
| US-20060257476-A1 | Tablet formulation | PHARMACIA & UPJOHN COMPANY | 2006-11-16 | — | — | US | claimed |
| US-7108864-B1 | Tablet formation | PHARMACIA & UPJOHN COMPANY (US) | 2006-09-19 | — | — | US | claimed |
| CN-1237958-C | Non-sustained release, non-chewable pharmaceutical tablet composition | UPJOHN CO (US) | 2006-01-25 | — | — | CN | claimed |
| CN-1301149-A | Lofuridine tablets | UPJOHN CO (US) | 2001-06-27 | — | — | CN | claimed |
| EP-1083885-A1 | DELAVIRDINE TABLET FORMULATION | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-21 | — | — | EP | claimed |
| US-6177101-B1 | NON-SUSTAINED RELEASE, NONCHEWABLE TABLET OF DELAVIRDINE MESYLATE, MICROCRYSTALLINE CELLULOSE, AND A BINDER SUCH AS HYDROXYPROPYL METHYLCELLULOSE, AND SUPERDISINTEGRANT, THE TABLET MADE WITHOUT HEATING, GRINDING OR SOLVENT | PHARMACIA & UPJOHN COMPANY | 2001-01-23 | — | — | US | claimed |
| WO-1999063970-A1 | DELAVIRDINE TABLET FORMULATION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195487-A1 | FORMULATIONS OF A CSF-1R INHIBITOR | CSF1R, CSF3R, IL1RN | MEN1 489/4885PTGS1 1173/4885PDE4A 1391/4885 |
| US-12447149-B2 | Formulations of vimseltinib | KDR, VIM, UGT1A7 | MEN1 1845/4885PTGS1 1511/4885PDE4A 1268/4885 |
| US-20250205236-A1 | FORMULATIONS OF VIMSELTINIB | KDR, VIM, UGT1A7 | MEN1 1845/4885PTGS1 1511/4885PDE4A 1268/4885 |
| US-20250205161-A1 | FORMULATIONS OF VIMSELTINIB | KDR, VIM, UGT1A7 | MEN1 1845/4885PTGS1 1511/4885PDE4A 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.